Global Cord Blood Corporation (CO) Income Statement Analysis

See more : Daito Me Holdings Co., Ltd (8455.TWO) Income Statement Analysis – Financial Results

Complete financial analysis of Global Cord Blood Corporation (CO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Cord Blood Corporation, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Global Cord Blood Corporation (CO)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.globalcordbloodcorp.com

About Global Cord Blood Corporation

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
Revenue	1.24B	1.16B	1.22B	986.75M	936.77M	759.98M	663.00M	635.12M	572.86M	526.12M	380.49M	339.53M	261.54M	0.00	0.00	0.00
Cost of Revenue	183.31M	178.95M	189.13M	186.03M	181.48M	142.64M	144.60M	130.61M	106.23M	106.62M	86.66M	77.38M	65.73M	0.00	0.00	0.00
Gross Profit	1.06B	980.69M	1.03B	800.73M	755.29M	617.34M	518.40M	504.51M	466.63M	419.50M	293.83M	262.16M	195.81M	0.00	0.00	0.00
Gross Profit Ratio	85.26%	84.57%	84.52%	81.15%	80.63%	81.23%	78.19%	79.44%	81.46%	79.73%	77.22%	77.21%	74.87%	0.00%	0.00%	0.00%
Research & Development	22.30M	23.77M	21.11M	14.69M	12.72M	10.37M	8.96M	9.91M	9.77M	8.46M	7.62M	6.96M	5.82M	0.00	0.00	0.00
General & Administrative	187.06M	174.36M	190.23M	169.32M	243.50M	189.94M	169.95M	131.68M	112.24M	108.05M	89.70M	83.79M	53.32M	11.20M	0.00	0.00
Selling & Marketing	241.73M	237.69M	261.96M	235.06M	219.20M	178.48M	148.16M	127.93M	112.69M	93.68M	61.68M	47.58M	39.48M	0.00	0.00	0.00
SG&A	428.79M	412.05M	452.19M	404.38M	462.70M	368.42M	318.11M	259.61M	224.93M	201.73M	151.37M	131.38M	92.80M	11.20M	4.01M	66.28K
Other Expenses	6.27M	8.16M	7.39M	5.70M	4.23M	5.97M	-113.00K	861.00K	2.21M	203.00K	0.00	0.00	0.00	594.98K	220.52K	166.41K
Operating Expenses	451.08M	435.82M	473.30M	419.07M	475.42M	352.47M	327.07M	269.52M	234.71M	210.19M	158.99M	138.34M	98.61M	11.80M	4.23M	232.69K
Cost & Expenses	634.39M	614.77M	662.43M	605.10M	656.91M	495.11M	471.67M	400.13M	340.93M	316.81M	245.65M	215.71M	164.34M	11.80M	4.23M	232.69K
Interest Income	32.61M	30.90M	25.36M	25.32M	21.94M	17.42M	18.22M	18.25M	16.87M	15.06M	13.43M	9.07M	6.41M	4.11M	0.00	250.79K
Interest Expense	0.00	0.00	0.00	0.00	3.26M	119.42M	107.97M	101.10M	70.08M	70.10M	3.29M	2.61M	2.43M	0.00	0.00	0.00
Depreciation & Amortization	19.91M	-26.82M	12.97M	52.37M	50.59M	50.48M	50.17M	50.61M	37.07M	35.87M	29.36M	23.48M	20.43M	3.92M	7.10M	250.79K
EBITDA	628.78M	518.05M	572.00M	404.75M	353.60M	333.71M	299.10M	306.33M	297.44M	256.96M	174.26M	151.71M	96.81M	-7.88M	2.87M	18.11K
EBITDA Ratio	50.58%	44.67%	46.83%	41.02%	37.75%	43.91%	45.11%	48.23%	51.92%	48.84%	45.80%	44.68%	37.02%	0.00%	0.00%	0.00%
Operating Income	608.87M	544.87M	559.03M	381.66M	279.86M	264.87M	191.33M	235.00M	231.93M	209.31M	134.84M	123.82M	97.19M	-11.80M	-4.23M	-232.69K
Operating Income Ratio	48.97%	46.99%	45.77%	38.68%	29.88%	34.85%	28.86%	37.00%	40.49%	39.78%	35.44%	36.47%	37.16%	0.00%	0.00%	0.00%
Total Other Income/Expenses	18.97M	65.88M	19.78M	-25.20M	23.67M	-98.55M	-50.00M	-79.88M	-41.00M	-51.13M	16.76M	8.32M	-17.53M	3.92M	7.10M	250.79K
Income Before Tax	627.84M	610.75M	578.81M	356.46M	303.54M	166.31M	141.33M	155.12M	190.92M	158.19M	151.60M	132.14M	79.66M	-7.88M	2.87M	18.11K
Income Before Tax Ratio	50.50%	52.67%	47.39%	36.12%	32.40%	21.88%	21.32%	24.42%	33.33%	30.07%	39.84%	38.92%	30.46%	0.00%	0.00%	0.00%
Income Tax Expense	118.35M	94.55M	101.08M	61.26M	62.66M	37.62M	50.00M	47.33M	58.40M	38.54M	9.63M	33.93M	24.77M	-4.11M	-7.47M	-18.11K
Net Income	501.07M	508.25M	470.72M	291.12M	237.10M	126.19M	90.97M	107.29M	131.90M	112.45M	131.98M	91.70M	49.18M	-7.88M	2.87M	18.11K
Net Income Ratio	40.30%	43.83%	38.54%	29.50%	25.31%	16.60%	13.72%	16.89%	23.03%	21.37%	34.69%	27.01%	18.80%	0.00%	0.00%	0.00%
EPS	4.12	4.18	3.87	2.40	1.99	1.59	1.25	1.36	1.60	1.49	1.79	1.31	0.69	-1.13	0.41	0.01
EPS Diluted	4.12	4.18	3.87	2.40	1.99	1.59	1.25	1.36	1.60	1.49	1.79	1.31	0.66	-1.13	0.41	0.01
Weighted Avg Shares Out	121.55M	121.55M	121.55M	121.30M	119.14M	79.36M	72.78M	78.89M	82.44M	75.47M	73.73M	70.00M	71.27M	7.00M	7.00M	1.49M
Weighted Avg Shares Out (Dil)	121.55M	121.55M	121.55M	121.30M	119.14M	79.36M	72.78M	78.89M	82.44M	75.47M	73.73M	70.00M	74.51M	7.00M	7.00M	1.49M

Global Cord Blood Corporation (CO) Investor Notice: Robbins LLP Reminds Stockholders of the Global Cord Blood Corporation Class Action

April 26, 2024businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $CO #CO--Robbins LLP is Investigating the Allegations that Rivian Automotive, Inc. (RIVN) Misled Investors Regarding Demand for its Products.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Global Cord Blood Corporation Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – CO, CORBF

April 24, 2024businesswire.com

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Global Cord Blood Corporation (NYSE: CO) (OTC: CORBF) between June 4, 2019 and...

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Global Cord

April 23, 2024headlinesoftoday.com

NEW YORK, April 23, 2024 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Global Cord Blood Corporation (“Global Cord” or the “Company”) (NYSE: CO) (OTC: CORBF) and reminds investors of the...

Global Cord Blood Corporation Announces Appointment of Joint Provisional Liquidators by The Grand Court Of The Cayman Islands

September 26, 2022headlinesoftoday.com

HONG KONG–(BUSINESS WIRE)–Global Cord Blood Corporation (NYSE: CO) (“GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that an order was made by the Grand...

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022

July 5, 2022prnewswire.com

Added 16,423 New Subscribers in 4QFY22 4QFY22 Revenues Down 1.7% YoY to RMB297.2 Million ($46.9 Million) 4QFY22 Gross Profit Down 0.5% YoY to RMB255.2 Million ($40.3 Million) 4QFY22 Operating Income Down 4.1% YoY to RMB142.1 Million ($22.4 Million) 4QFY22 Non-GAAP...